NERV — Minerva Neurosciences Balance Sheet
0.000.00%
Last trade - 00:00- $21.96m
- -$12.86m
Annual balance sheet for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 45.9 | 25.4 | 60.8 | 36.1 | 40.9 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 47.1 | 27.4 | 62.2 | 40.2 | 42 |
| Net Property, Plant And Equipment | 0.278 | 0.102 | 0 | 0.016 | 0.011 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 77.5 | 57.6 | 77.1 | 55.1 | 56.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 6.63 | 3.16 | 2.82 | 1.38 | 3.34 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 49.7 | 4.96 | 69.1 | 75.1 | 85.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 27.8 | 52.7 | 7.98 | -20 | -28.5 |
| Total Liabilities & Shareholders' Equity | 77.5 | 57.6 | 77.1 | 55.1 | 56.9 |
| Total Common Shares Outstanding |